Investigational Drug Information for ASP0367
✉ Email this page to a colleague
What is the development status for investigational drug ASP0367?
ASP0367 is an investigational drug.
There have been 7 clinical trials for ASP0367.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 17th 2021.
The most common disease conditions in clinical trials are Muscular Dystrophies, Renal Insufficiency, and Liver Diseases. The leading clinical trial sponsors are Astellas Pharma Global Development, Inc., Astellas Pharma Inc, and [disabled in preview].
There are eleven US patents protecting this investigational drug and fifty-seven international patents.
Summary for ASP0367
| US Patents | 11 |
| International Patents | 57 |
| US Patent Applications | 34 |
| WIPO Patent Applications | 19 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2021-05-17) |
| Vendors | 28 |
Recent Clinical Trials for ASP0367
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate an ASP0367 Solution in Healthy Male Participants | Astellas Pharma Global Development, Inc. | Phase 1 |
| A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People | Astellas Pharma Global Development, Inc. | Phase 1 |
| A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | Astellas Pharma Global Development, Inc. | Phase 1 |
Clinical Trial Summary for ASP0367
Top disease conditions for ASP0367
Top clinical trial sponsors for ASP0367
US Patents for ASP0367
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP0367 | ⤷ Start Trial | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Salk Institute for Biological Studies | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Salk Institute for Biological Studies | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Salk Institute for Biological Studies | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | Crystalline and salt forms of PPAR agonist compounds | Astellas Engineered Small Molecules Us Inc | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | Compositions and methods for treating cancer with anti-BCMA immunotherapy | Lentigen Technology Inc | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | Crystalline and salt forms of PPAR agonist compounds | Astellas Engineered Small Molecules Us Inc | ⤷ Start Trial |
| ASP0367 | ⤷ Start Trial | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | Salk Institute for Biological Studies | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP0367
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP0367 | Argentina | AR106298 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | Australia | AU2016333963 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | Australia | AU2019283837 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | Australia | AU2020281069 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | Brazil | BR112018006866 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | Canada | CA3000431 | 2035-10-07 | ⤷ Start Trial |
| ASP0367 | China | CN108349904 | 2035-10-07 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
